Idexx Laboratories (IDXX) Total Current Liabilities (2009 - 2026)

Idexx Laboratories has reported Total Current Liabilities for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 5.21% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 5.21% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 7.58% from the prior year.
• Total Current Liabilities was $1.3 billion for Q2 2026 at Idexx Laboratories, down from $1.3 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.3 billion in Q1 2026, with the low at $883.9 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 87.73% in 2022, then dropped 24.23% in 2023.
• Over 5 years, Total Current Liabilities stood at $1.2 billion in 2022, then retreated by 23.0% to $951.5 million in 2023, then grew by 12.23% to $1.1 billion in 2024, then climbed by 7.58% to $1.1 billion in 2025, then advanced by 12.09% to $1.3 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.3 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.